AGP Picks
View all

Bringing you the latest news on politics

Provided by AGP

Got News to Share?

My Election Journal: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on My Election Journal.

Press releases published on April 13, 2026

J&F Announces Offering of New Senior Notes  and Commences Exchange Offer and Consent Solicitation for  Eldorado’s 8.500% Senior Notes due 2032
Notice of AGM

Notice of AGM

Media Advisory — You Are Invited: HII’s Approach to Supporting the US Navy’s “Hedge Strategy”
VGTel, Inc. (OTCID:VGTL) Announces Provisional Patent Filing and Public Release of MiraLink™ Signal Intelligence Framework
Northrop Grumman and U.S. Air Force Accelerate Sentinel Program Momentum
Equinor ASA: Forslag om kapitalnedsettelse fra selskapets styre
Equinor ASA: Proposal on capital reduction from the company’s board of directors
AtlasClear Holdings Files Regulatory Applications to Acquire Commercial Bancorp, Parent of Farmers State Bank
Xeriant Completes Critical Internal Fire Testing on NEXBOARD™ and Advances to Third-Party Certification Phase
Safe Pro Launches Next Gen AI Powered NODE-X Miniaturized Edge Processing for Drone Footage at U.S. Army Exercise
ParaZero Secures a Follow-on Order for DefendAir Counter-UAS, Including Personal Net Launchers, Net Pods, and Training
Bombardier Announces April 15, 2026 as the Start of its New Normal Course Issuer Bid
Bombardier annonce le 15 avril 2026 comme date de début de sa nouvelle offre publique de rachat d’actions dans le cours normal de ses activités
Abaxx Exchange Recognized as Organised Market Place by ACER
ImageneBio Announces $30 Million Private Placement
Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer
Transgene annonce la fin de la randomisation des patients de la partie Phase 2 de l’essai clinique évaluant TG4050 dans le traitement adjuvant des cancers de la tête et du cou
Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria
Communiqué de presse : Dupixent de Sanofi et Regeneron approuvé dans l'UE comme premier médicament ciblé contre l'urticaire chronique spontanée chez les jeunes enfants
UK Startups Come to London to Rumble With Policymakers

Share us

on your social networks:

Sign up for:

My Election Journal

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.